Inclusion Criteria:

- Age > 18 years;

- Diagnosis of histologically confirmed stages IB2 (> 4 cm) to IVA prickle-cell
carcinoma or adenocarcinoma or uterine cervix adenosquamous carcinoma, according to
FIGO system,7 (see Appendix A for guidance about staging);

- Measurable disease according to RECIST 1.139 or at least disease evaluable through
imaging methods and/or gynecological examination (magnetic resonance imaging (MRI)
scans within six weeks prior to randomization will be accepted, computed tomography
will accepted in case MRI is contraindicated);

- Indication of definitive treatment with chemotherapy and radiation therapy, at the
investigator's discretion;

- Performance status < 2, according to the Eastern Cooperative Oncology Group criteria
40 (ECOG; see Appendix C);

- Adequate body functions, indicated by:Serum creatinine < 1.2 mg/100 mL; Creatinine
clearance > 60 mL/min (estimate); Bilirubin up to 1.5-fold the upper limit of normal
(ULN) and transaminases, alkaline phosphatase and gamma-glutamyltransferase up to
2.5-fold the ULN; Leucocytes > 3,000/μL; Neutrophils > 1,500/μL; Hemoglobin > 10
g/dL; Platelets > 80,000/μL;

- Signed informed consent form.

Exclusion Criteria:

- Para-aortic lymph nodes involvement through radiological and/or surgical staging, at
investigator's discretion;

- Current severe comorbidity that, in the investigator's opinion, would put the patient
at a significantly higher risk or will jeopardize protocol compliance;

- Current bowel inflammatory disease;

- Current major neurological or psychiatric disease, including clinically significant
dementia and seizures, at the investigator's discretion;

- Known hypersensitivity or allergic reactions to study treatment;

- Current uncontrolled hypercalcemia (> 11,5 mg/dL, that is, grade > 1 according to
Common Terminology Criteria for Adverse Events [CTCAE] v4.02, of US National Cancer
Institute)41;

- Know HIV positive status (enrollment of patients with hepatitis B or C is at the
investigator's discretion);

- Pregnancy or lactation;

- Female patients, as well as their partners, who wish to become pregnant or are
unwilling to use an appropriate contraceptive method throughout the study period.